Drugs / TAK-360
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT07633301 | Jun 2026 → Nov 2027 expected | narcolepsy 1 | Takeda | Recruiting | No outcome recorded |
| Phase 2 | NCT06952699 | May 2025 → Nov 2026 expected | narcolepsy without cataplexy | Takeda | Recruiting | No outcome recorded |
| Phase 2 | NCT06812078 | Feb 2025 → Nov 2026 expected | idiopathic hypersomnia | Takeda | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07646678 | Jun 2026 → Jun 2031 expected | idiopathic hypersomnia, narcolepsy 1, narcolepsy without cataplexy | Takeda | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-360 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06812078 ↗ |
| Route | Oral | “Participants will receive TAK-360 tablets, orally, for 4 weeks.” NCT06812078 ↗ |